The topical JAK inhibitor ruxolitinib (brand name Opzelura) has been recommended in final draft guidance by the National Institute for Health and Care Excellence (NICE) for eligible patients with non-segmental vitiligo.
The first licensed treatment for vitiligo in the NHS, ruxolitinib will be available to more than 80,000 individuals aged 12 years and over who have non-segmental vitiligo with facial involvement and for whom other topical first-line treatments have not worked or are not suitable.
The cream is applied twice daily to affected areas of the skin and works by calming the immune system’s attack on pigment-producing cells, helping repair the skin cells so they regain their natural colour. Results are usually checked after six months.
Clinical trials showed ruxolitinib significantly improved facial repigmentation compared with a placebo, with many patients being four times more likely to see a return of skin colour to affected areas and over six times more likely to report their vitiligo becoming much less noticeable or no longer noticeable.
Until now, treatment options for non-segmental vitiligo have mostly been limited to interventions that camouflage the condition, or steroid creams that can thin and damage the skin if used long-term. Light therapy is also offered, but it requires repeated hospital visits and does not always produce lasting results.
Following its approval by the Medicines and Healthcare products Regulatory Agency in 2023, ruxolitinib had been rejected for NHS use in August 2025, but following a rapid review and complex negotiations, NHS England secured a deal with manufacturer Incyte to enable its approval for use on the NHS.
‘A historic milestone’ for vitiligo
Commenting on the news, Abigail Hurrell, chief executive officer of The Vitiligo Society, said: ‘Today’s approval of ruxolitinib represents a historic milestone and the first time the NHS has recognised and funded a dedicated repigmentation treatment.
‘This decision acknowledges the significant psychological, social and medical impact of vitiligo and marks a fundamental shift towards the equitable care our community has long deserved.’
Indeed, while often not physically painful, for many people, vitiligo can be emotionally distressing. When it affects the face, it can have a significant impact on people’s confidence, sense of identity and mental health, which the prescription of ruxolitinib can now help to address.
Professor Meghana Pandit, national medical director at NHS England, said: ‘For many people, vitiligo isn’t just a change in skin colour – it can affect how they see themselves and how they feel every day, particularly when it involves the face.
‘We also know the condition can have a particularly significant impact on people with darker skin tones, where changes in pigmentation are more visible.’
Pav Korpal, a patient expert who was a member of previous NICE committees looking at vitiligo treatments, said: ‘As an Indian with brown skin, my vitiligo is more visible. As a young child, I was often called vile names and bullied as a result, causing me distress and anxiety. This led me to me seeking off label treatments, which have often been hit and miss.
‘Getting the news that ruxolitinib, an effective treatment expressly for vitiligo, is being recommended gives me renewed optimism. Treating the physical symptoms will also help to manage the psychological effects of this disease.’
Ruxolitinib and evidence‑based care
Gurdeep Romanay, chairperson of The Vitiligo Society added: ‘For decades, our community has waited for a licensed treatment to be recognised and funded by the NHS — and now, at last, that moment has arrived.
‘This approval is not only a medical milestone; it is a recognition of every person who has felt unseen, unheard, or dismissed because of a visible difference. It tells our community that your experiences matter, your wellbeing matters, and your condition deserves real, evidence‑based care.’
NHS England has confirmed it will make ruxolitinib available through specialist dermatology services within three months of final guidance being published.
The Vitiligo Society has warned patients that access may vary between hospitals during the rollout as local pathways may take time to establish.
This article was originally published by our sister publication Hospital Healthcare Europe.
